Related Experiment Video

Updated: May 10, 2026

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Targeting GRP78 and antiestrogen resistance in breast cancer

Katherine L Cook1, Pamela A G Clarke, Robert Clarke

  • 1Department of Oncology & Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA.

Future Medicinal Chemistry
|June 6, 2013
PubMed

Insights

Estrogen receptor-positive breast cancer often develops resistance to endocrine therapies. Targeting GRP78, a key regulator of the unfolded protein response, may help overcome this resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Breast cancer is a leading cancer in women, with over 70% of cases being estrogen receptor-positive (ER+).
  • Endocrine therapies like tamoxifen are common for ER+ breast cancer but often fail due to drug resistance, a significant clinical challenge.
  • The unfolded protein response (UPR) has emerged as a key player in the development of endocrine resistance.

Purpose of the Study:

  • To investigate the role of GRP78, a master regulator of the UPR, in endocrine-resistant breast cancer.
  • To explore the potential of targeting GRP78 to overcome antiestrogen therapy resistance.

Main Methods:

  • Analysis of GRP78 levels in endocrine-resistant breast cancer.
  • Investigating the impact of GRP78 on cellular processes relevant to breast cancer survival.
  • Reviewing compounds that modulate GRP78 activity.

Main Results:

  • GRP78 was found to be elevated in endocrine-resistant breast cancer.
  • Elevated GRP78 levels were directly correlated with reduced responsiveness to antiestrogen therapy.
  • GRP78 influences multiple cellular pathways crucial for breast cancer cell survival.

Conclusions:

  • GRP78 plays a critical role in the development of endocrine resistance in breast cancer.
  • Targeting GRP78, potentially in combination with existing antiestrogens, offers a promising strategy to improve treatment outcomes for resistant breast cancers.

More Related Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...